Anti-Human RIF1 (Clone FHC-155) – Purified No Carrier Protein

RIF1 synthetic peptide ASQGLLSSIENSESDSSEAK

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FHC-155-35-2 activity is directed against human RIF1.

RIF1 is a negative regulator of DNA replication that controls the replication timing of genomic segments during S phase in many species, from yeast to humans¹. RIF1 delays helicase activation within certain regions of the genome, thereby delaying their replication until later in S phase. DNA replication does not occur uniformly during cell division; rather, replication is initiated stochastically, with helicase activation critical to replication kinetics and timing. Open and active chromatin regions are often replicated early in S phase, but condensed, transcriptionally inactive chromatin is often replicated late in S phase. RIF1 plays an important role in these timing events. Additionally, RIF1 is involved in DNA double-strand break repair and protecting cells from ultrafine anaphase bridges.

Loss of RIF1 activity leads to global changes in replication timing in fission yeast, fruit flies, mice, and humans, resulting in genome instability, increased genetic mutation, and activation of the checkpoint response¹. Additionally, dysregulation of RIF1 has been reported in breast cancer, and a positive correlation between RIF1 and lung carcinoma has been found². The potential role for RIF1 in cervical cancer is being investigated.

FHC-155-35-2 was generated in rabbit using a phosphorylated (pS1542), non-modified peptide sequence ASQGLLSSIENSESDSSEAK of human RIF1³. FHC-155-35-2 was developed for use in immuno-MRM assays and does not work in Western blotting assays.

RIF1 is widely expressed and is especially found in human embryonic stem cells. Expression peaks in the late G2/S phase of the cell cycle.

TP53BP1; SHLD2; ERCC6; ASTE1

1 Richards L, Das S, Nordman JT. 13(3):550. 2022.
2 Kordowitzki P, Graczyk S, Mechsner S, et al. Aging Dis. 15(2):535-545. 2024.
3 https://research.fredhutch.org/content/dam/stripe/paulovich/files/PaulovichLab_Mab_AvailableForImmuno-MRM_11092020.pdf